Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal
Executive Summary
A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer
You may also be interested in...
Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says
Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale
Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says
Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale
Loestrin transaction gets further FTC scrutiny
FTC has requested additional information on Barr's proposed acquisition of rights to Galen's Loestrin oral contraceptive line (1"The Pink Sheet" Sept. 15, 2003, p. 37). Barr had hoped to close the deal by Feb. 1; the company is "unable to determine the impact" of FTC's request for additional information...